hGH fragment is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-06-01. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
In April 2023, Lula met with union leaders and took part in the Brazil-Spain Business Forum in Madrid. On 26 April, Lula, alongside several of his cabinet ministers, met with Spanish prime minister Pedro Sánchez at the Moncloa Palace, where he signed two different deals regarding education and work areas, which includes facilitating student exchange programmes between universities in both countries, expanding cooperation between in higher education and adopting regulations for IT companies Later on that day, Lula, Rosângela and FM Mauro Vieira met with King Felipe VI at the Royal Palace of Madrid. In March 2023, Lula received Sánchez in Brasília ahead of the 2024 G20 Rio de Janeiro summit to discuss trade relations between Brazil and Spain including the EU-Mercosur Association Agreement as well the reform of world institutions such as the United Nations and the World Bank.
In the "Cave of the Sixteen sword bearers", the murals of the sixteen sword-bearers are located in the lateral left and right corridors around the central pillar, simulating a procession of devotees. The sides of the main room are occupied by panels showing groups around seated Buddhas, while the vault is decorated with a myriad of small Buddhas with emanating flames.
Although higher energies can produce more astatine-211, it will produce unwanted astatine-210 that decays to toxic polonium-210 as well. Instead, the maximum energy of the particle accelerator is set to be below or slightly above the threshold of astatine-210 production, in order to maximize the production of astatine-211 while keeping the amount of astatine-210 at an acceptable level.
== Clinical significance == Levels of the hormone prolactin within the body can indicate various conditions. Normal prolactin levels support reproductive and metabolic functions, while elevated prolactin levels (hyperprolactinemia), and low prolactin levels (hypoprolactinemia) can indicate an underlying medical disorder. Levels of prolactin within the body can also be affected by factors such as pregnancy, stress, and certain medications. Due to the widespread distribution of prolactin receptors across the body’s organs and tissues, elevated levels of prolactin can simultaneously influence multiple organ systems of the body. While prolactin cell levels rise during pregnancy and lactation, they can also rise due to stress, pain, exercise, sexual intercourse, and food consumption. Hyperprolactinemia (elevated prolactin levels) can be caused by excessive thyrotropin-releasing hormone production or decreased dopamine levels. This may cause symptoms in both males and females such as infertility, erectile dysfunction, and irregular periods. Excessive release of prolactin can be due to a prolactinoma, a tumor of the pituitary gland. The tumor itself may not cause symptoms, but may cause an increased production of prolactin and decreased levels of estrogen and testosterone. Symptoms due to a prolactinoma may include infertility, a decrease in sexual desire, and osteoporosis. In men, symptoms may include erectile dysfunction, enlarged breast tissue, and decreased body hair. In women, symptoms may include breast discharge, irregular menstrual cycles, acne, and increased body hair.
Sources: en.wikipedia.org
== Career and writing == After leaving Oxford, Halliwell briefly lectured at the Portsmouth Polytechnic (1973–74). He took up a position as lecturer at King's College London in 1974, remaining there until 2000, rising to the position of Professor of Medical Biochemistry in the Division of Pharmacology. He also simultaneously held a visiting professorship at the University of California, Davis, United States (1995–99). After a 1998 sabbatical at the National University of Singapore (NUS), he moved there in 2000 as chair of the biochemistry department. As of 2018 he is a professor in the department of biochemistry at the NUS Yong Loo Lin School of Medicine. Halliwell is currently the Senior Advisor, Academic Appointments and Research Excellence, Office of the Provost, at the National University of Singapore (NUS). He is also Chairman of the Biomedical Research Advisory Council (BMAC), Agency for Science, Technology & Research (A*STAR). Halliwell served as the NUS's first Deputy President (Research and Technology) in 2006–15, founding the Graduate School for Integrative Sciences and Engineering, and overseeing a more than doubling in the university's research grants and the creation at NUS of Singapore's first Research Centre of Excellence (RCEs). He was subsequently appointed Senior Advisor to the NUS President. His textbook, Free Radicals in Biology and Medicine, co-written with John M. C. Gutteridge, is considered "an authoritative text in the field".
the unstretched protein molecules formed a helix (which he called the α-form) the stretching caused the helix to uncoil, forming an extended state (which he called the β-form). Although incorrect in their details, Astbury's models of these forms were correct in essence and correspond to modern elements of secondary structure, the α-helix and the β-strand (Astbury's nomenclature was kept), which were developed by Linus Pauling, Robert Corey and Herman Branson in 1951 (see below); that paper showed both right- and left-handed helices, although in 1960 the crystal structure of myoglobin showed that the right-handed form is the common one. Hans Neurath was the first to show that Astbury's models could not be correct in detail, because they involved clashes of atoms. Neurath's paper and Astbury's data inspired H. S. Taylor, Maurice Huggins and Bragg and collaborators to propose models of keratin that somewhat resemble the modern α-helix. Two key developments in the modeling of the modern α-helix were: the correct bond geometry, thanks to the crystal structure determinations of amino acids and peptides and Pauling's prediction of planar peptide bonds; and his relinquishing of the assumption of an integral number of residues per turn of the helix. The pivotal moment came in the early spring of 1948, when Pauling caught a cold and went to bed. Being bored, he drew a polypeptide chain of roughly correct dimensions on a strip of paper and folded it into a helix, being careful to maintain the planar peptide bonds.
=== First Trump administration === Sanders criticized President Trump for appointing multiple billionaires to his cabinet. He criticized Trump's rolling back President Obama's Clean Power Plan, noting the scientifically reported effect on climate change of human activity and citing Trump's calling those reports a hoax. He called for caution on the Syrian Civil War, saying, "It's easier to get into a war than out of one." In 2017, he promised to defeat "Trump and Trumpism and the Republican right-wing ideology". Sanders gave an online reply to Trump's January 2018 State of the Union address in which he called Trump "compulsively dishonest" and criticized him for initiating "a looming immigration crisis" by ending the Deferred Action for Childhood Arrivals program. He voiced concern about Trump's failure to mention the finding that Russia had interfered in the 2016 election and "will likely interfere in the 2018 midterms we will be holding ... Unless you have a very special relationship with Mr. Putin". On January 6, 2021, Trump supporters attacked the United States Capitol. Sanders commented: "[Trump] has made it clear that he will do anything to remain in power – including insurrection and inciting violence [and he] will go down in history as the worst and most dangerous president in history." Sanders voted to convict Trump on both articles of his first impeachment trial in 2020 (for pressuring a foreign leader to investigate Joe Biden), and again on the sole article of his second impeachment trial in 2021 (for inciting the Capitol attack).
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.